3rd Quarter - Report

LMH STRATEGIC SOLUTIONS for ALNYLAM PHARMACEUTICALS, INC.

Period 3rd Quarter 2026 Filed Oct 19, 2026 Signed by Beth Anne Cole

Official filing
Firm
LMH STRATEGIC SOLUTIONS
Client
ALNYLAM PHARMACEUTICALS, INC.
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.

LobbyistCovered position, as disclosed
SOPHIE KHANAHMADI Legislative Asst., Rep. Martha Roby; Legislative Asst., Rep. Lee Terry; Staff Asst./LC, Senator Jeff Sessions
ALANNA TEMME Legislative Director, U.S. Representative Jon Porter

Contacted: SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 946 (119th), H.R. 1672 (119th), S. 1862 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.